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Introduction: Despite drastic increases in antipsychotic prescribing in youth, data are still limited regarding their
safety in this vulnerable population, necessitating additional tools for capturing long-term, real world data.
Methods: We present SENTIA (SafEty of NeurolepTics in Infancy and Adolescence; https://SENTIA.es), an online
registry created in 2010 to track antipsychotic adverse effects in Spanish youth <18 years old currently taking or
initiating with any antipsychotic treatment. SENTIA collects information on sociodemographic, diagnostic and
treatment characteristics, past personal medical/psychiatric history, healthy lifestyle habits and treatment adherence.
Additionally, efficacy and adverse effect data are recorded including the Children’s Global Assessment Scale; Clinical
Global Impressions scale for Severity and Improvement, the Safety Monitoring Uniform Report Form, Simpson-Angus
Scale, Abnormal Involuntary Movement Scale, vital signs, blood pressure, and EKG. Finally, fasting blood is drawn for
hematology, electrolytes, renal, liver and thyroid function, glucose, insulin, lipid, prolactin and sex hormone levels.
Initially, a diagnostic interview and several psychopathology scales were also included. Patients are assessed regularly
and followed even beyond stopping antipsychotics.
Results: Since 01/17/2011, 85 youth (11.5 ± 2.9 (range = 4-17) years old, 70.6% male) have been included at one
inaugural center. After a mean duration of 17 ± 11 (range = 1-34) months, 78.8% are still actively followed. For feasibility
reasons, the diagnostic interview and detailed psychopathology scales were dropped. The remaining data can be
entered in <30 minutes. Several additional centers are currently being added to SENTIA.
Conclusions: Implementation of a systematic online pharmacovigilance system for antipsychotic adverse effects in
youth is feasible and promises to generate important information.
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The use of antipsychotics has dramatically increased in
children and adolescents in recent years. This sharp in-
crease stands, however, in stark contrast to the relative
paucity of data from controlled investigations (Olfson
et al. 2012; Vitiello et al. 2009; Correll 2008; Zuddas et al.
2011). Indeed, few methodologically sound studies exist* Correspondence: marujapalanca@gmail.com
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reproduction in any medium, provided the origon the safety and efficacy of second-generation antipsy-
chotics in pediatric populations (Vitiello et al. 2009; Jensen
et al. 2007). Moreover, long-term evidence for the safety of
antipsychotics in children and adolescents is scant (Aman
et al. 2005). Importantly, most of the antipsychotics are
prescribed off-label, and age-specific dose guidelines and
adverse reaction profiles are often not available in these
populations (Panagiotopoulos et al. 2010). The severity of
some adverse effects of antipsychotics in adults, and the
few available data in children and adolescents has raised
concerns about the benefit/risk ratio of antipsychotics in
youth (Vitiello et al. 2009; Correll 2008). Taken together,r. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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tools aimed at collecting data on antipsychotic adverse
effects in pediatric populations that reflect and are
generalizable to clinical practice settings and populations.
In recent years, several networks across the world have
been created to routinely assess the safety of psychotropic
medications in youth (Ronsley et al. 2012; Seida et al.
2012). The Child and Adolescent Psychiatry Trials Net-
work (CAPTN) was created to collect “real life” data of
pediatric patients treated with antidepressants drugs in
the US (March et al. 2004; Shapiro et al. 2009). In Canada,
the Canadian Alliance for Monitoring Effectiveness and
Safety of Antipsychotics in Children (CAMESA) has ac-
tively collected data on the safety of antipsychotics in
youth (Pringsheim et al. 2011; Ho et al. 2011). In Europe,
the Therapeutic Drug Monitoring (TADS) run by the
German-Austrian Swiss “Competence Network on TDM in
Child and Adolescent Psychiatry” (Mehler-Wex et al. 2009)
and the Pediatric Atypical Antipsychotic Monitoring
Safety Study (PAMS) in the United Kingdom (Rani et al.
2009) have been developed.
The present article is aimed at presenting SENTIA
(SafEty of NeurolepTics in Infancy and Adolescence), an
online registry (https://SENTIA.es) created for the long-
term pharmacovigilance and safety evaluation of antipsy-
chotics in children and adolescents in Spain (Figure 1).
Aims of SENTIA
SENTIA was created in 2010 within the Clinical Program
for Safe Antipsychotic Use in Children and Adolescents,
run jointly by the Departments of Psychiatry and Clinical
Pharmacology of the Puerta de Hierro University Hospital
in Madrid, Spain.
The principal objective of the Clinical Program for Safe
Antipsychotics in Infancy and Adolescence is to facilitate
the safest use of antipsychotics in children and adolescents
through the early prevention and detection of antipsychotic
adverse events. Moreover, close monitoring and longtermFigure 1 Overall appearance of online data recording (https://SENTIAfollow-up also aims to enhance treatment adherence as well
as patient and family alliance, with the ultimate goal to im-
prove overall outcomes.
The Registry enrolled the first patient on 01/17/2011.
Currently, all clinical information comes from Puerta de
Hierro University Hospital (Madrid, Spain) and one refer-
ring community mental health center. After this pilot
phase, SENTIA will be open to all Institutions attending
children and adolescents across Spain and additional cen-
ters are currently being added.
Description of SENTIA
SENTIA is an online database platform, which permits
the registration of collected data in relation to short and
long-term safety of antipsychotics in children and adoles-
cents. This online application makes multi-centre partici-
pation possible. SENTIA is supported by grants from the
Spanish Ministry of Health and Social Politics (EC10-040)
and Mutua Madrileña Foundation (2010 and 2013).
SENTIA includes patients <18 years old currently taking
or initiating treatment with any antipsychotic either as
monotherapy or polytherapy. Patients can be recruited
from different clinical settings of the participating hos-
pitals. There are no clinical exclusion criteria. Patients
with severe mental retardation or neurological abnor-
malities are also included, although some collected pa-
rameters are not applicable. Those who accept to be
included in the online Registry are entered after the
caregivers’ signing of the Informed Consent.
Children and adolescents are regularly monitored.
Antipsychotic-naïve patients are monitored before starting
treatment, and after 1, 3 and 6 months, and then on a 6-
monthly basis. Patients included in the program who are
currently on treatment for more than one month are
monitored on a 6-monthly basis. The clock is reset and
monitoring is carried out like in an antipsychotic naïve
subject whenever a new antipsychotic is started as part of
a switch or restarting procedure. Patients are followed for,.es).
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and even after the discontinuation of antipsychotic treat-
ment and, if possible, into adulthood.
The selection of the systematically collected biological
and physical safety parameters and scales was based on a
literature review of possible adverse effects of antipsychotics
in pediatric populations and on the recommendations of
several scientific associations and expert groups dealing
with children and adolescents treated with antipsychotics
(Panagiotopoulos et al. 2010; Seida et al. 2012; Correll et al.
2006). We defined an adverse reaction as a response to a
medicinal product which is noxious and unintended. We
register all suspected adverse effects, independent from the
causality category (probable, possible or unlikely) and
whether it is related to the antipsychotic or to another me-
dicinal product. If an anomaly is detected, a specialist re-
lated to the abnormal data, −e.g., cardiologist in the case of
an EKG abnormality- and the patients’ physician(s), −i.e.,
child psychiatrist, pediatrician - are informed, so that they
can take any necessary action. Thus, in addition to the
regularly scheduled assessments, additional tests are per-
formed as clinically necessary.
Design of SENTIA (data recording)
SENTIA comprises information on sociodemographic,
diagnostic and therapeutic characteristics (age, gender,
race, clinical primary diagnosis and comorbidities, target
symptom(s) that motivates the antipsychotic prescrip-
tion, time since these symptoms started, etc.), past per-
sonal medical and psychiatric history (i.e., drug allergies,
perinatal complications, breastfeeding, psychomotor de-
velopment and relevant medical history), healthy lifestyle
habits (i.e., diet, physical exercise), past psychotropic
use, and medication adherence, using a self-developed
questionnaire to patients and to caregivers (How many
doses did you miss since the last visit? Who supervises
the youth’s medication taking?). Further, the following
validated instruments for the assessment of the diagno-
sis and psychopathology of children and adolescents are
included: the Mini International Neuropsychiatric Inter-
view (Mini-KID) (Sheehan et al. 2010); Screening Ques-
tionnaire for Autistic Spectrum Disorder (ASSQ) (Ehlers
et al. 1999); the Children’s Global Assessment Scale (CGAS)
(Lundh et al. 2010); and the Clinical Global Impressions
scale for Severity (CGI-S) and Improvement (CGI-I)
(Busner and Targum 2007) and Achenbach Child Behav-
iour Checklist (CBCL) (Achenbach and Edelbrock 1981).
The potential adverse effects are closely monitored dur-
ing each office visit using the Safety Monitoring Uniform
Report Form (SMURF) (Greenhill et al. 2004), a specific
adverse effect scale for pediatric psychotropic use. Given
that there is not validated scale in the pediatric population,
the SMURF was translated ad hoc into Spanish with the
authors’ authorization. Furthermore, in order to bettermonitor any potential neurological adverse effects, we used
the validated Spanish versions of the modified Simpson-
Angus Scale (SAS) (Simpson and Angus 1970) and the Ab-
normal Involuntary Movement Scale (AIMS) (Guy 1976).
Further, the risk for metabolic syndrome, cardiovascular,
cardiac, endocrine and other relevant adverse events are
specifically monitored through complete physical examin-
ation, including height, weight, body mass index (BMI) and
waist circumference, and sexual development, assessed
using Tanner staging (Desmangles et al. 2006); an electro-
cardiogram (PR and QTc intervals), systolic and diastolic
blood pressure and pulse rate, respectively. Finally, fasting
blood work is obtained for full blood count, coagulation,
serum glucose, electrolytes, hepatic and renal function tests,
lipid profile, insulin, thyroid hormones, sex hormones, and
prolactin.
Ethical aspects
The Puerta de Hierro University Hospital Research Ethics
Committee approved SENTIA in 2010, October. In ac-
cordance with current legislation, informed consent is ob-
tained from parents or legal guardians and also from the
patient if he/she is over 12 years old. Collected data are
treated anonymously, in compliance with the local Data
Protection Law (Ley Orgánica 15/1999 on confidentiality
of personal data).
Personal contact details are not included in the online
database. Contact details are found only on informed
consent forms kept in a restricted access file. The infor-
mation collected in this register is anonymous for the
persons performing the data analysis or writing reports
or papers since patients are identified by a six-digit code.
The project leaders have access to all included data to
verify that the information entered in the database is re-
liable and corresponds with the data from the patient’s
medical history.
The registry database is the property of the program
leaders (IPM and BRA), who are responsible for any ne-
cessary organization and data analysis.
The project is registered in the European Network of
Centres for Pharmacoepidemiology and Pharmacovigi-
lance (ENCEPP). This is a new initiative established by
the European Medicines Agency (EMA) which is seeking
to promote the conduct of such studies and establish
standards for post-marketing safety evaluations.
Initial results
Since 01/17/2011 until 30/12/2013, 85 youth (11.5 ± 2.9
(range = 4-17) years old, 70.6% male) have been enrolled at
one center. At the moment of inclusion 60% were naive to
antipsychotics therapy. After a mean duration of 17 ± 11
(range = 1-34) months, 78.8% are still followed. For feasibil-
ity reasons, the time consuming diagnostic interviews
(MINI-kid and ASSQ) and the CBCL were dropped. The
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visit and complete data entry takes <30 minutes. At present,
several additional centers are being included in SENTIA.
Limitations
A potential limitation of SENTIA is that participation is
voluntary. Thus, we could potentially introduce a selection
bias. We register the basic characteristics of patients pre-
scribed antipsychotics but not entering into the registry in
order to assess the representativeness of the included
population. Another issue is that of missing data. Some of
the required scales/measurements are clearly less time
consuming and easier to comply with than others. Thus,
there might be some imbalances and areas of missing data,
in the sense that some information will be more easily
assessed as part of SENTIA than others. As mentioned
above, for feasibility reasons, we decided to drop the very
time consuming interviews (MINI-kid and ASSQ) and the
CBCL, focusing the clinical effort of adverse effect monitor-
ing and global assessment of efficacy using the CGAS and
CGI. The foreseen incorporation of new centers entail new
challenges, such as the need for suitable procedures to
guarantee quality of data: monitoring, audits as well as the
need to a more mature design of the governing boards of
the program, with a revised and more participative Scientific
Committee. With regards to specific training to the evalua-
tors we have chosen to skip a mandatory centralized training
as we wish to apply a methodology that would be feasible
and enable rolling out of SENTIA to many additional cen-
ters. Nevertheless, periodical newsletters and workshops will
be scheduled as a tool to promote consistencyt.
Two major strengths of SENTIA are its standardized
format and longitudinal design that will provide missing
and much needed long-term safety and tolerability data,
and its naturalistic design, thus giving a clear picture of
real-life use and safety of antipsychotics.Conclusions
The field is in need of new tools that can help monitor
and detect long-term, delayed and developmental adverse
events of antipsychotics in pediatric patients. SENTIA, an
online pharmacovigilance registry, seems to be a feasible
and promising tool for the systematic monitoring of anti-
psychotic adverse effects in children and adolescents. In
particular, the high retention rate is encouraging. The suc-
cessful implementation of SENTIA in other centers needs
to be tested and long-term adverse effect data will con-
tinue to be collected. Finally, routine clinical monitoring
of potentially problematic long-term adverse effects of an-
tipsychotics need to be monitored regularly in clinical
practice, even outside of pharmacovigilance or research
projects (Correll 2008; Pringsheim et al. 2011; Ho et al.
2011; Correll et al. 2009).Availability and requirements
The web address at which the database is available is
https://sentia.es/gvpp/login.xhtml; use of this database is
restricted to the research team. Nevertheless for any
consultation or additional information to make contact
with the author.
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